AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Aytu BioPharma Inc. (AYTU)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.36

-0.02 (-1.45%)

At close: Feb 20, 2025, 3:58 PM

1.40

2.94%

After-hours: Feb 20, 2025, 06:16 PM EST

undefined% (undefined)

Bid	1.35
Market Cap	8.39M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.08
PE Ratio (ttm)	-0.65
Forward PE	n/a
Analyst	Buy

Ask	1.4
Volume	74,658
Avg. Volume (20D)	30,391
Open	1.36
Previous Close	1.38
Day's Range	1.35 - 1.40
52-Week Range	1.30 - 3.45
Beta	undefined

About AYTU

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Sep 25, 2008

Employees 102

Stock Exchange NASDAQ

Ticker Symbol AYTU

Website https://aytubio.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for AYTU stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago

-0.72%

Aytu BioPharma shares are trading higher after the... Unlock content with Pro Subscription

3 months ago

-11.43%

Aytu BioPharma shares are trading lower. The company reported Q1 financial results.

News

1 week ago · seekingalpha.com

Aytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call Transcript

Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q2 2025 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Robert Blum - Investor Relations, Lytham Partners Josh Disbrow - Chief Executive ...

1 week ago · accessnewswire.com

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Net income of $0.8 million Adjusted EBITDA1 of $1.3 million Pediatric Portfolio net revenue up 86% sequentially First quarterly sequential prescription increase for both ADHD and Pediatric portfolios ...

2 weeks ago · accessnewswire.com

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

DENVER, CO / ACCESS Newswire / February 5, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its ...